Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Andexanet Alfa Corrects the Interference of Direct Factor Xa Inhibitors on Lupus Anticoagulant Testing

Ross I Baker, MD, Grace Gilmore, Scott McGregor, BPharm

Blood (2016) 128 (22): 2626.

https://doi.org/10.1182/blood.V128.22.2626.2626

Published: 2016

Journal Articles

Assessment of Algorithms to Identify Patients with Thrombophilia Following Venous Thromboembolism

Wendy Hsiao, BS, Thomas Delate, PhD MS, Daniel M Witt, PharmD, Melissa R Meyer, PharmD, Alan Go, MD, Margaret Fang, MD MPH, Benjamin Kim, MD MPhil

Blood (2014) 124 (21): 3513.

https://doi.org/10.1182/blood.V124.21.3513.3513

Published: 2014

Journal Articles

Usefulness of Dilute Russell’s Viper Venom Clotting Time (DRVVT) for the Routine Monitoring of New Oral Anticoagulants

Debra Hoppensteadt, PhD, Jake Kola, Mark Brayne, Omer Iqbal, MD, Jawed Fareed, PhD

Blood (2014) 124 (21): 1537.

https://doi.org/10.1182/blood.V124.21.1537.1537

Published: 2014

Journal Articles

Circulating Levels of Rivaroxaban Provide Different Results in Different Clot Based and Amidolytic Assays. a Study on Patients Treated with Two Different Dosages of Rivaroxaban

Debra Hoppensteadt, PhD, Daneyal Syed, BS, Mateja Jezovnik, Pavel Poredos, Sermin Tetik, Omer Iqbal, MD, Jeanine M. Walenga, PhD, Jawed Fareed, PhD

Blood (2014) 124 (21): 5084.

https://doi.org/10.1182/blood.V124.21.5084.5084

Published: 2014

Journal Articles

Is Dilute Russell’s Viper Venom Time a Useful Assay To Monitor Patients Treated By Rivaroxaban Or Dabigatran Etexilate?

Jonathan Douxfils, Pharm D, PhD Student, Anne Tamigniau, Pharm D, Bernard Chatelain, Professor, Bérangère Devalet, M.D., Pierre Wallemacq, Professor, Paul Hjemdahl, Professor, Yuko Rönquist-Nii, Jean-Michel Dogné, Professor, François Mullier, PhD

Blood (2013) 122 (21): 3634.

https://doi.org/10.1182/blood.V122.21.3634.3634

Published: 2013

Journal Articles

Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell's Viper Venom Times For The Monitoring Of New Oral Anticoagulants

Debra Hoppensteadt, Ph.D., Jeanine M. Walenga, PhD, Josephine Cunanan, Omer Iqbal, MD, Jawed Fareed, Ph.D.

Blood (2013) 122 (21): 3642.

https://doi.org/10.1182/blood.V122.21.3642.3642

Published: 2013

Journal Articles

The Challenge Of Russell’s Viper Venom Time Interpretation For Lupus Anticoagulant Diagnosis: A Two-Year Retrospective Institutional Review

Geoffrey D. Wool, MD, PhD, Scott C. Kogan, MD

Blood (2013) 122 (21): 1131.

https://doi.org/10.1182/blood.V122.21.1131.1131

Published: 2013

Journal Articles

Baseline Laboratory Parameters Potentially Associated with Thrombophilia in Patients with Chronic ITP.

Raymond S.M. Wong, Kalpana Bakshi, BS, MS, Andres Brainsky, MD

Blood (2012) 120 (21): 2191.

https://doi.org/10.1182/blood.V120.21.2191.2191

Published: 2012

Journal Articles

Effects of Dabigatran and Rivaroxaban On Routine and Specialized Coagulation Assays: A Study Using Actual Patient Plasma Samples

Tyler W. Smith, MD, FRCPC, Leslie Zypchen, MD, FRCPC, Cedric J. Carter, MD, FRCPC, Annie Tran, Pamela Colley, NP, Kenneth Gin, MD, FRCPC, Philip Teal, MD, FRCPC, Bassam A. Masri, MD, FRCSC, Agnes Y.Y. Lee, MD, MSc, FRCPC

Blood (2012) 120 (21): 23.

https://doi.org/10.1182/blood.V120.21.23.23

Published: 2012

Journal Articles

A Retrospective Review of Diagnoses Coexisting with a Positive Lupus Anticoagulant In a Community Hospital

Scott Brook, MD, Gauri Badhwar, DO, Megha Kothari, MD, Colette Spaccavento, MD, Keith Brunckhorst, MD

Blood (2010) 116 (21): 5121.

https://doi.org/10.1182/blood.V116.21.5121.5121

Published: 2010

Journal Articles

Clinical Significance of Indeterminate Lupus Anticoagulant (LAC) Results.

Khaldoun J. Alkayed, MD, Kandice Kottke-Marchant, MD, PhD

Blood (2009) 114 (22): 3988.

https://doi.org/10.1182/blood.V114.22.3988.3988

Published: 2009

Journal Articles

Effects of the Novel, Oral, Direct Factor Xa Inhibitor Rivaroxaban on Coagulation Assays

Meyer Michel Samama, Lena Le Flem, Celine Guinet, Elisabeth Perzborn, Jean-Luc Martinoli, François Depasse

Blood (2008) 112 (11): 3028.

https://doi.org/10.1182/blood.V112.11.3028.3028

Published: 2008

Journal Articles

Rivaroxaban — An Oral, Direct Factor Xa Inhibitor — Prevents Arterial Thrombotic Occlusion in Electrolytically Injured Rat Carotid Arteries.

Barbara Haertlein, BS, Tom J. Parry, Ph.D., Cailin Chen, Ph.D., Elizabeth Perzborn, Ph.D., Patricia Andrade-Gordon, Ph.D., Bruce P. Damiano, Ph.D.

Blood (2007) 110 (11): 3–4003.

https://doi.org/10.1182/blood.V110.11.3-a.3-a

Published: 2007

Journal Articles

The Prevalence and Clinical Significance of IgA Antiphospholipid Antibodies (aPL).

Yu-Min Shen, MD, Anna Dyszkiewicz-Korpanty, MD, Ray Lee, MD, Jyoti Balani, MD, Eugene Frenkel, MD, Ravindra Sarode, MD

Blood (2005) 106 (11): 2647.

https://doi.org/10.1182/blood.V106.11.2647.2647

Published: 2005

Journal Articles

Comparison of aPTT (Platelin LS®) and Dilute Russell’s Viper Venom (Viperquik LA Test®) for the Screening of Lupus Anticoagulant in Patients with Venous Thromboembolism.

Celso A. Roprigues, MD, Aline A. Martinez, MD, Vania M. Morelli, MD, Raniely C. Silveira, BSc, Maria Aparecida E. Noguti, BSc, Dayse M. Lourenco, MD

Blood (2005) 106 (11): 4122.

https://doi.org/10.1182/blood.V106.11.4122.4122

Published: 2005

NARROW

Andexanet Alfa Corrects the Interference of Direct Factor Xa Inhibitors on Lupus Anticoagulant Testing

Assessment of Algorithms to Identify Patients with Thrombophilia Following Venous Thromboembolism

Usefulness of Dilute Russell’s Viper Venom Clotting Time (DRVVT) for the Routine Monitoring of New Oral Anticoagulants

Circulating Levels of Rivaroxaban Provide Different Results in Different Clot Based and Amidolytic Assays. a Study on Patients Treated with Two Different Dosages of Rivaroxaban

Is Dilute Russell’s Viper Venom Time a Useful Assay To Monitor Patients Treated By Rivaroxaban Or Dabigatran Etexilate?

Prothrombinase Induced Clotting Time (PICT) and Commercially Available Diluted Russell's Viper Venom Times For The Monitoring Of New Oral Anticoagulants

The Challenge Of Russell’s Viper Venom Time Interpretation For Lupus Anticoagulant Diagnosis: A Two-Year Retrospective Institutional Review

Baseline Laboratory Parameters Potentially Associated with Thrombophilia in Patients with Chronic ITP.

Effects of Dabigatran and Rivaroxaban On Routine and Specialized Coagulation Assays: A Study Using Actual Patient Plasma Samples

A Retrospective Review of Diagnoses Coexisting with a Positive Lupus Anticoagulant In a Community Hospital

Clinical Significance of Indeterminate Lupus Anticoagulant (LAC) Results.

Effects of the Novel, Oral, Direct Factor Xa Inhibitor Rivaroxaban on Coagulation Assays

Rivaroxaban — An Oral, Direct Factor Xa Inhibitor — Prevents Arterial Thrombotic Occlusion in Electrolytically Injured Rat Carotid Arteries.

The Prevalence and Clinical Significance of IgA Antiphospholipid Antibodies (aPL).

Comparison of aPTT (Platelin LS®) and Dilute Russell’s Viper Venom (Viperquik LA Test®) for the Screening of Lupus Anticoagulant in Patients with Venous Thromboembolism.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only